Clinical trial: EPs® 7630 show great results
14.02.2023 - A clinicaltrial assessed the use of our active pharmaceutical ingredient EPs® 7630 in children ages one to five with acute bronchitis. This trial was conducted in conjunction with Professor Wolfgang Kamin from the pediatric hospital of Hamm and has now been published in the international journal Frontiers in Pediatrics.
In this randomized trial, children were given EPs®7630 for seven days, either as a syrup (n=403) or as a solution (n=188). Over 90% of the children showed an improvement or remission in symptoms. The parents were also satisfied or very satisfied with treatment in 86% of cases. The number of adverse events in both treatment groups was comparably low and revealed no safety concerns.
The study found that an improvement in health status and complaints were comparably positive in treatment with EPs® 7630. EPs® 7630 was equally safe and well-tolerated in children between the ages of one and five.
The original publication "Kamin W, Behre U, Helm K, Reling B, Funk P, Malek FA. Safety of Pelargonium extract EPs 7630 in young children with acute bronchitis. Front. Pediatr. Sec. Pediatric Infectious Diseases 2023; 11. doi: 10.3389/fped.2023.1107984" is available for free at the link:
https://www.frontiersin.org/articles/10.3389/fped.2023.110798